To further enhance the efficacy of PD-1/PD-L1 monoclonal antibodies in the treatment of B-cell lymphoma, various combination regimens have been proposed, including other immune checkpoint inhibitors, co-stimulatory molecular agonists, and other types of therapeutic antibodies. This evidence concerns the gene CD274 and B-cell non-Hodgkin lymphoma.